Travere Therapeutics, Inc.
The company develops and provides treatments for rare diseases. Its product candidates include Sparentan (RE-021), a treatment for focal segmental glomerulosclerosis (FSGS), a major cause of end-stage renal disease, and Pegtibatinase (TVT-058), a new treatment candidate for homocystinuria (HCU). The company is based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | California |
Employees | 380 |
Founded | |
Financials | |
|---|---|
Market Capitalization | 746.06M |
Revenue | 183.22M |
Operating Income | -411.80M |
Operating Margin | -224.75% |
Net Income | -161.13M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 5246 / 5373 |
Sector : Healthcare | 1108 / 1144 |
Industry : Biotechnology | 624 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 2672 / 5565 |
Sector : Healthcare | 361 / 1182 |
Industry : Biotechnology | 152 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4999 / 5436 |
Sector : Healthcare | 1006 / 1164 |
Industry : Biotechnology | 550 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 3128 / 5330 |
Sector : Healthcare | 355 / 1174 |
Industry : Biotechnology | 75 / 667 |